$CDTX
Cidara Therapeutics, Inc. Stock $cdtx

$cdtx Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-K Financial Statement

#000161061824000041 Filed on April 22, 2024

Income Statement

Concept	2024 Q2	2023 Q4	2023 Q1
Revenue	$302.0K	$17.58M	$25.99M
YoY Change	-96.03%	72.06%	265.59%
Cost Of Revenue		$1.136M	$0.00
YoY Change
Gross Profit		$16.45M	$26.11M
YoY Change
Gross Profit Margin		93.54%	100.45%
Selling, General & Admin	$4.746M	$7.169M	$4.298M
YoY Change	43.38%	109.13%	-17.41%
% of Gross Profit		43.59%	16.46%
Research & Development	$6.657M	$15.35M	$18.72M
YoY Change	-61.15%	-23.46%	-7.2%
% of Gross Profit		93.34%	71.69%
Depreciation & Amortization	$57.00K	$38.00K	$32.00K
YoY Change	128.0%	31.03%	-17.95%
% of Gross Profit		0.23%	0.12%
Operating Expenses	$96.29M	$22.52M	$23.01M
YoY Change	370.95%	-4.11%	-9.29%
Operating Profit	-$95.98M	-$6.074M	$2.977M
YoY Change	648.06%		-116.3%
Interest Expense	$1.774M	$527.0K	$232.0K
YoY Change	184.75%	225.31%	-1260.0%
% of Operating Profit			7.79%
Other Income/Expense, Net	$1.774M		$232.0K
YoY Change	184.75%		-1260.0%
Pretax Income	-$94.21M	-$5.547M	$3.209M
YoY Change	671.71%	-57.67%	-117.55%
Income Tax	$0.00	$64.00K	$0.00
% Of Pretax Income			0.0%
Net Earnings	-$91.21M	-$5.611M	$3.209M
YoY Change	638.12%	-58.05%	-117.55%
Net Earnings / Revenue	-30201.66%	-31.91%	12.35%
Basic Earnings Per Share	-$19.99		$0.03
Diluted Earnings Per Share	-$19.99	-$0.06	$0.03
COMMON SHARES
Basic Shares Outstanding	91.24M shares	90.43M shares	89.01M shares
Diluted Shares Outstanding	4.564M shares		101.2M shares

Balance Sheet

Concept	2024 Q2	2023 Q4	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$164.4M	$35.78M	$47.98M
YoY Change	225.93%	9.31%	31.48%
Cash & Equivalents	$164.4M	$35.78M	$47.98M
Short-Term Investments
Other Short-Term Assets	$1.870M	$2.734M	$5.686M
YoY Change	-57.24%	-58.13%	-15.59%
Inventory		$6.097M
Prepaid Expenses
Receivables	$2.349M	$16.25M	$25.83M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$168.6M	$60.86M	$79.49M
YoY Change	170.87%	34.95%	52.84%
LONG-TERM ASSETS
Property, Plant & Equipment	$602.0K	$5.127M	$270.0K
YoY Change	102.69%	2209.46%	12.97%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$104.0K	$1.048M	$1.061M
YoY Change	-90.2%	-2.24%	4.12%
Total Long-Term Assets	$4.769M	$6.175M	$2.248M
YoY Change	-17.0%	147.1%	-31.63%
TOTAL ASSETS
Total Short-Term Assets	$168.6M	$60.86M	$79.49M
Total Long-Term Assets	$4.769M	$6.175M	$2.248M
Total Assets	$173.4M	$67.03M	$81.74M
YoY Change	154.99%	40.84%	47.82%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.288M	$3.772M	$3.980M
YoY Change	20.48%	160.68%	39.11%
Accrued Expenses	$6.225M	$38.33M	$9.078M
YoY Change	-37.89%	399.65%	-1.69%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$254.0K	$218.0K	$0.00
YoY Change			-100.0%
Total Short-Term Liabilities	$39.64M	$67.42M	$35.66M
YoY Change	26.17%	124.94%	11.08%
LONG-TERM LIABILITIES
Long-Term Debt	$445.0K	$575.0K	$0.00
YoY Change
Other Long-Term Liabilities	$2.333M	$7.247M	$19.24M
YoY Change	-88.97%	-64.69%	5.5%
Total Long-Term Liabilities	$2.778M	$7.822M	$19.24M
YoY Change	-86.87%	-61.89%	5.5%
TOTAL LIABILITIES
Total Short-Term Liabilities	$39.64M	$67.42M	$35.66M
Total Long-Term Liabilities	$2.778M	$7.822M	$19.24M
Total Liabilities	$42.42M	$75.24M	$54.90M
YoY Change	-19.31%	49.0%	9.06%
SHAREHOLDERS EQUITY
Retained Earnings	-$543.0M	-$441.4M	-$403.8M
YoY Change	30.5%	8.45%	2.12%
Common Stock	$673.9M	$433.2M	$430.6M
YoY Change	56.17%	7.22%	7.54%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$130.9M	-$8.210M	$26.84M
YoY Change
Total Liabilities & Shareholders Equity	$173.4M	$67.03M	$81.74M
YoY Change	154.99%	40.84%	47.82%

Cashflow Statement

Concept	2024 Q2	2023 Q4	2023 Q1
OPERATING ACTIVITIES
Net Income	-$91.21M	-$5.611M	$3.209M
YoY Change	638.12%	-58.05%	-117.55%
Depreciation, Depletion And Amortization	$57.00K	$38.00K	$32.00K
YoY Change	128.0%	31.03%	-17.95%
Cash From Operating Activities	-$103.8M	-$12.72M	-$10.90M
YoY Change	-3777.53%	-39.42%	-53.84%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$175.0K	$94.00K
YoY Change	-100.0%	1844.44%	11.9%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00	-$175.0K	-$94.00K
YoY Change	-100.0%	1844.44%	11.9%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net			$0.00
YoY Change			-100.0%
Cash From Financing Activities	239.1M	4.000K	$26.24M
YoY Change	-91721.07%	-99.4%	-4394.11%
NET CHANGE
Cash From Operating Activities	-103.8M	-12.72M	-$10.90M
Cash From Investing Activities	0.000	-175.0K	-$94.00K
Cash From Financing Activities	239.1M	4.000K	$26.24M
Net Change In Cash	135.4M	-12.89M	$15.25M
YoY Change	5415.53%	-36.63%	-162.73%
FREE CASH FLOW
Cash From Operating Activities	-$103.8M	-$12.72M	-$10.90M
Capital Expenditures	$0.00	$175.0K	$94.00K
Free Cash Flow	-$103.8M	-$12.90M	-$10.99M
YoY Change	-3922.47%	-38.62%	-53.6%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92121
CY2023	dei	City Area Code CityAreaCode	(858)
CY2023	dei	Local Phone Number LocalPhoneNumber	752-6170
CY2023	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 Par Value
CY2023	dei	Trading Symbol TradingSymbol	“CDTX”
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity File Number EntityFileNumber	001-36912
CY2023	dei	Entity Registrant Name EntityRegistrantName	CIDARA THERAPEUTICS, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-1537286
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	6310 Nancy Ridge Drive,
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 101
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	35778000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5833000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2734000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	60855000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	557000	usd
CY2023	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	59570000	usd
CY2022	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	64448000	usd
CY2023	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	1995000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1995000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	191000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-22488000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	11000000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-33312000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	443000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	272000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	97951000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-24483000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-33503000	usd
CY2022Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	45302480	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8099624	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.78
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y7M24D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	48000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3233558	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.02
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	25750	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.83
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	641417	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	3.12
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10666015	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.23
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y8M19D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	57000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	10666015	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	2.23
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y8M19D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	57000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	7236987	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.75
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y8M15D
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	54000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.72
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.51
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	2400000	usd
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001610618
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego,
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	true
CY2023	dei	Document Fin Stmt Restatement Recovery Analysis Flag DocumentFinStmtRestatementRecoveryAnalysisFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	100200000	usd
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	91235020	shares
CY2023	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2023	dei	Auditor Location AuditorLocation	San Diego, California
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	32731000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	16246000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	6097000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	0	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6530000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	45094000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	222000	usd
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	782000	usd
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	0	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3788000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1099000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1048000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1072000	usd
CY2023Q4	us-gaap	Assets Assets	67030000	usd
CY2022Q4	us-gaap	Assets Assets	47487000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3772000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1447000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14177000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7672000	usd
CY2023Q4	us-gaap	Accrual For Taxes Other Than Income Taxes Current AccrualForTaxesOtherThanIncomeTaxesCurrent	18040000	usd
CY2022Q4	us-gaap	Accrual For Taxes Other Than Income Taxes Current AccrualForTaxesOtherThanIncomeTaxesCurrent	11534000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5034000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4922000	usd
CY2023Q4	cdtx	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer Liability Current RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent	25095000	usd
CY2022Q4	cdtx	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer Liability Current RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent	14614000	usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	218000	usd
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	0	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1082000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1211000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	67418000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	41400000	usd
CY2023Q4	cdtx	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer Liability Noncurrent RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent	4245000	usd
CY2022Q4	cdtx	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer Liability Noncurrent RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent	20525000	usd
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	575000	usd
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	0	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3002000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	usd
CY2023Q4	us-gaap	Liabilities Liabilities	75240000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	61925000	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	90601999	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	90601999	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	72470440	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	72470440	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	9000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	7000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	433212000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	404055000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-441431000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-418500000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-8210000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-14438000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	67030000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	47487000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4335000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	usd
CY2023	us-gaap	Revenues Revenues	63905000	usd
CY2022	us-gaap	Revenues Revenues	64448000	usd
CY2023	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	1523000	usd
CY2022	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	0	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	68532000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	77405000	usd
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	18333000	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	20546000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	88388000	usd
CY2022	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	191000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-22931000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-22931000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-33584000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-33584000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.26
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.26
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.48
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.48
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	87427439	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	87427439	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	69857698	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	69857698	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	13104000	usd
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	140000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	3532000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-33584000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-14438000	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	21000	usd
CY2023	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	122000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	3061000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-22931000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-8210000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-22931000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-33584000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	3061000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	3532000	usd
CY2023	cdtx	Operating Lease Right Of Use Amortization OperatingLeaseRightOfUseAmortization	1158000	usd
CY2022	cdtx	Operating Lease Right Of Use Amortization OperatingLeaseRightOfUseAmortization	981000	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	112000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	143000	usd
CY2023	us-gaap	Capitalized Contract Cost Amortization CapitalizedContractCostAmortization	77000	usd
CY2022	us-gaap	Capitalized Contract Cost Amortization CapitalizedContractCostAmortization	0	usd
CY2023	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	6000	usd
CY2022	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	0	usd
CY2023	us-gaap	Paid In Kind Interest PaidInKindInterest	5000	usd
CY2022	us-gaap	Paid In Kind Interest PaidInKindInterest	1000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	10413000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	477000	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	6097000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-3735000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2440000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	8886000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2371000	usd
CY2023	cdtx	Increase Decrease In Accrual For Taxes Other Than Income Taxes IncreaseDecreaseInAccrualForTaxesOtherThanIncomeTaxes	6506000	usd
CY2022	cdtx	Increase Decrease In Accrual For Taxes Other Than Income Taxes IncreaseDecreaseInAccrualForTaxesOtherThanIncomeTaxes	3945000	usd
CY2023	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	235000	usd
CY2022	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	203000	usd
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-5799000	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	2646000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-973000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1052000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-22432000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-28473000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	505000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	118000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-505000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-118000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	17256000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2023	cdtx	Proceeds From Issuance Of Common Stock In Underwritten Public Offering ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering	8707000	usd
CY2022	cdtx	Proceeds From Issuance Of Common Stock In Underwritten Public Offering ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering	2362000	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	21000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
CY2023	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	usd
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	720000	usd
CY2023	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	usd
CY2022	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	2593000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	25984000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-951000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	3047000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-29542000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	32731000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	62273000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	35778000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	32731000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	40000	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	797000	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	11000	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	69000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	788000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	0	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3847000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2023	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	122000	usd
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	140000	usd
CY2023	cdtx	Proceeds From Public Offering Net Of Issuance Costs Prepaid Expenses Other Current Assets And Other Assets ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesOtherCurrentAssetsAndOtherAssets	0	usd
CY2022	cdtx	Proceeds From Public Offering Net Of Issuance Costs Prepaid Expenses Other Current Assets And Other Assets ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesOtherCurrentAssetsAndOtherAssets	8000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-441400000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	35800000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. generally accepted accounting principles, or GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting period. The Company evaluates its estimates and assumptions on an ongoing basis. The most significant estimates in the Company’s consolidated financial statements relate to estimated collaboration expenses related to the Company’s collaboration and license agreements, certain accruals, including those related to nonclinical and clinical activities, and the stand-alone selling price of performance obligations associated with the Company’s </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">collaboration and license agreements. Although the estimates are based on the Company’s knowledge of current events, comparable companies, and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</span></div>
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1099000	usd
CY2022Q4	us-gaap	Assets Assets	47487000	usd
CY2022Q4	us-gaap	Accrual For Taxes Other Than Income Taxes Current AccrualForTaxesOtherThanIncomeTaxesCurrent	11534000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1211000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	41400000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	61925000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-418500000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-14438000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	47487000	usd
CY2022	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	64448000	usd
CY2022	us-gaap	Revenues Revenues	64448000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	77405000	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	20546000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	97951000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-33503000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-33312000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-33584000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-33584000	usd
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.48
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.48
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	69857698	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	69857698	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	13104000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-33584000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-14438000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-33584000	usd
CY2022	cdtx	Operating Lease Right Of Use Amortization OperatingLeaseRightOfUseAmortization	981000	usd
CY2022	cdtx	Accrued Indirect Tax Liabilities AccruedIndirectTaxLiabilities	3945000	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	2646000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1052000	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company’s financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in government insured financial institutions in excess of government insured limits. The Company invests its cash balances in financial institutions that it believes have high credit quality, has not experienced any losses on such accounts and does not believe it is exposed to significant credit risk.</span></div>
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	33826119	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	40025543	shares
CY2023Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	35778000	usd
CY2023Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	35778000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	32731000	usd
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	32731000	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	2691000	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	0	usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	3406000	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	0	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	0	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	0	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	6097000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	0	usd
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	0	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3747000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3380000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3190000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3158000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	557000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	222000	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	100000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	100000	usd
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023	cdtx	Number Of Votes Entitlement For Each Share Held NumberOfVotesEntitlementForEachShareHeld	1	vote
CY2023	cdtx	Common Stock Dividends In Arrears Or Default CommonStockDividendsInArrearsOrDefault	0	usd
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	38225338	shares
CY2023Q4	cdtx	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer Liability Current RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent	25095000	usd
CY2023Q4	cdtx	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer Liability Noncurrent RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent	4245000	usd
CY2023Q4	cdtx	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer Liability RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability	29340000	usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	393000	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	248000	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	50000	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	24000	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	443000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	272000	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	443000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	272000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-4723000	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-7029000	usd
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-186000	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-247000	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	260000	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	415000	usd
CY2023	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	2076000	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	1877000	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	-54000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	491000	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	6373000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-19684000	usd
CY2023	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	519000	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	-10423000	usd
CY2023	cdtx	Effective Income Tax Rate Reconciliation162 M Deferred Tax Asset Limitation Amount EffectiveIncomeTaxRateReconciliation162MDeferredTaxAssetLimitationAmount	128000	usd
CY2022	cdtx	Effective Income Tax Rate Reconciliation162 M Deferred Tax Asset Limitation Amount EffectiveIncomeTaxRateReconciliation162MDeferredTaxAssetLimitationAmount	82000	usd
CY2023	cdtx	Effective Income Tax Rate Reconciliation382 Nol And Tax Asset Limitation Amount EffectiveIncomeTaxRateReconciliation382NOLAndTaxAssetLimitationAmount	0	usd
CY2022	cdtx	Effective Income Tax Rate Reconciliation382 Nol And Tax Asset Limitation Amount EffectiveIncomeTaxRateReconciliation382NOLAndTaxAssetLimitationAmount	37513000	usd
CY2023	cdtx	Effective Income Tax Rate Reconciliation Expired Stock Awards Amount EffectiveIncomeTaxRateReconciliationExpiredStockAwardsAmount	174000	usd
CY2022	cdtx	Effective Income Tax Rate Reconciliation Expired Stock Awards Amount EffectiveIncomeTaxRateReconciliationExpiredStockAwardsAmount	1052000	usd
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	28000	usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-21000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	443000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	272000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	35506000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	42043000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	9747000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	9327000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	136000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	160000	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	25871000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	14706000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1424000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1385000	usd
CY2023Q4	cdtx	Deferred Tax Assets Leasing Arrangements DeferredTaxAssetsLeasingArrangements	1112000	usd
CY2022Q4	cdtx	Deferred Tax Assets Leasing Arrangements DeferredTaxAssetsLeasingArrangements	275000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	5951000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	5620000	usd
CY2023Q4	cdtx	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Taxes Other Than Income Taxes DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsTaxesOtherThanIncomeTaxes	4114000	usd
CY2022Q4	cdtx	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Taxes Other Than Income Taxes DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsTaxesOtherThanIncomeTaxes	2617000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	725000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1018000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	84586000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	77151000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	83086000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	76713000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1500000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	438000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	214000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	189000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Other Capitalized Costs DeferredTaxLiabilitiesDeferredExpenseOtherCapitalizedCosts	244000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Other Capitalized Costs DeferredTaxLiabilitiesDeferredExpenseOtherCapitalizedCosts	0	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	1042000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	249000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1500000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	438000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration	5300000	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	6400000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	19700000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	11500000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	9700000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	11015000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	23990000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	552000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	497000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	47000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	13472000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	11520000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	11015000	usd
CY2023Q4	us-gaap	Loss Contingency Pending Claims Number LossContingencyPendingClaimsNumber	0	claim
CY2023Q4	us-gaap	Lessee Finance Lease Term Of Contract1 LesseeFinanceLeaseTermOfContract1	P36M
CY2023Q4	cdtx	Lessee Finance Lease Monthly Rate LesseeFinanceLeaseMonthlyRate	25009	usd
CY2023Q4	cdtx	Lessee Finance Lease Option Purchase Equipment LesseeFinanceLeaseOptionPurchaseEquipment	1	usd
CY2023Q4	us-gaap	Lessee Finance Lease Discount Rate LesseeFinanceLeaseDiscountRate	0.080
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	275000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	300000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	300000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	25000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	900000	usd
CY2023Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	107000	usd
CY2023Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	793000	usd
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset Before Accumulated Amortization FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization	788000	usd
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	6000	usd
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	782000	usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	218000	usd
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	575000	usd
CY2023Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	793000	usd
CY2023Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P3Y1M6D
CY2023	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	0	usd
CY2023Q2	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P36M
CY2023Q2	cdtx	Lessee Operating Lease Monthly Rate LesseeOperatingLeaseMonthlyRate	133371	usd
CY2023Q2	cdtx	Lessee Operating Lease Annual Rate Increase LesseeOperatingLeaseAnnualRateIncrease	0.04
CY2023Q2	cdtx	Number Of Operating Lease Options For Extension NumberOfOperatingLeaseOptionsForExtension	2	option
CY2023Q2	cdtx	Lessee Operating Lease Option Renewal Term LesseeOperatingLeaseOptionRenewalTerm	P2Y
CY2023Q4	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.120
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1600000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1665000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1731000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	4996000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	912000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	4084000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3788000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1082000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3002000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	4084000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	1300000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	1200000	usd
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	1600000	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	1300000	usd
CY2023	cdtx	Lessee Variable Lease And Short Term Leases Term Of Lease Included In Operating Lease Cost LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost	P30D
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	47976000	usd
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	36488000	usd
CY2023Q1	us-gaap	Restricted Cash RestrictedCash	0	usd
CY2022Q1	us-gaap	Restricted Cash RestrictedCash	1482000	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	26121000	usd
CY2022Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	8783000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5711000	usd
CY2022Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5254000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	79808000	usd
CY2022Q1	us-gaap	Assets Current AssetsCurrent	52007000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	270000	usd
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	239000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	836000	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1846000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1061000	usd
CY2022Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1019000	usd
CY2023Q1	us-gaap	Assets Assets	81975000	usd
CY2022Q1	us-gaap	Assets Assets	55111000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	4026000	usd
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	2861000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9108000	usd
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9954000	usd
CY2023Q1	us-gaap	Accrual For Taxes Other Than Income Taxes Current AccrualForTaxesOtherThanIncomeTaxesCurrent	11795000	usd
CY2022Q1	us-gaap	Accrual For Taxes Other Than Income Taxes Current AccrualForTaxesOtherThanIncomeTaxesCurrent	7942000	usd
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5843000	usd
CY2022Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3079000	usd
CY2023Q1	cdtx	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer Liability Current RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent	15790000	usd
CY2022Q1	cdtx	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer Liability Current RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent	14260000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	920000	usd
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1090000	usd
CY2023Q1	us-gaap	Loans Payable Current LoansPayableCurrent	0	usd
CY2022Q1	us-gaap	Loans Payable Current LoansPayableCurrent	1481000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	47482000	usd
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	40667000	usd
CY2023Q1	cdtx	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer Liability Noncurrent RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent	19386000	usd
CY2022Q1	cdtx	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer Liability Noncurrent RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent	17229000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	usd
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	920000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	66868000	usd
CY2022Q1	us-gaap	Liabilities Liabilities	58816000	usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q1	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	9000	usd
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	7000	usd
CY2023Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	430585000	usd
CY2022Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	399678000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-415487000	usd
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-403390000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	15107000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-3705000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	81975000	usd
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	55111000	usd
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	90024562	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	90024562	shares
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	69049247	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	69049247	shares
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	50430000	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24637000	usd
CY2023Q2	us-gaap	Restricted Cash RestrictedCash	0	usd
CY2022Q2	us-gaap	Restricted Cash RestrictedCash	370000	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5483000	usd
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4833000	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	2388000	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	0	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4373000	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6706000	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	62674000	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	36546000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	297000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	201000	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4307000	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1602000	usd
CY2023Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1061000	usd
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1013000	usd
CY2023Q2	us-gaap	Assets Assets	68339000	usd
CY2022Q2	us-gaap	Assets Assets	39362000	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1899000	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	3091000	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10022000	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8567000	usd
CY2023Q2	us-gaap	Accrual For Taxes Other Than Income Taxes Current AccrualForTaxesOtherThanIncomeTaxesCurrent	13431000	usd
CY2022Q2	us-gaap	Accrual For Taxes Other Than Income Taxes Current AccrualForTaxesOtherThanIncomeTaxesCurrent	10582000	usd
CY2023Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3582000	usd
CY2022Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3464000	usd
CY2023Q2	cdtx	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer Liability Current RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent	14975000	usd
CY2022Q2	cdtx	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer Liability Current RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent	14730000	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	861000	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1129000	usd
CY2023Q2	us-gaap	Loans Payable Current LoansPayableCurrent	0	usd
CY2022Q2	us-gaap	Loans Payable Current LoansPayableCurrent	370000	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	44770000	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	41933000	usd
CY2023Q2	cdtx	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer Liability Noncurrent RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent	17551000	usd
CY2022Q2	cdtx	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer Liability Noncurrent RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent	15351000	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3601000	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	621000	usd
CY2023Q2	us-gaap	Liabilities Liabilities	65922000	usd
CY2022Q2	us-gaap	Liabilities Liabilities	57905000	usd
CY2023Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q2	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q2	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	9000	usd
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	7000	usd
CY2023Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	431519000	usd
CY2022Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	400599000	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-429111000	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-419149000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	2417000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-18543000	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	68339000	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	39362000	usd
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	90251746	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	90251746	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	69238508	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	69238508	shares
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	48670000	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	53078000	usd
CY2023Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3178000	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5042000	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	2901000	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	0	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3712000	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5779000	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	58461000	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	63899000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	580000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	173000	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4050000	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1354000	usd
CY2023Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1053000	usd
CY2022Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1295000	usd
CY2023Q3	us-gaap	Assets Assets	64144000	usd
CY2022Q3	us-gaap	Assets Assets	66721000	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	3661000	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	4244000	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11772000	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8162000	usd
CY2023Q3	us-gaap	Accrual For Taxes Other Than Income Taxes Current AccrualForTaxesOtherThanIncomeTaxesCurrent	14689000	usd
CY2022Q3	us-gaap	Accrual For Taxes Other Than Income Taxes Current AccrualForTaxesOtherThanIncomeTaxesCurrent	11314000	usd
CY2023Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4457000	usd
CY2022Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4117000	usd
CY2023Q3	cdtx	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer Liability Current RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent	14679000	usd
CY2022Q3	cdtx	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer Liability Current RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent	15249000	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	970000	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1169000	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	50228000	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	44255000	usd
CY2023Q3	cdtx	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer Liability Noncurrent RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent	16504000	usd
CY2022Q3	cdtx	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer Liability Noncurrent RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent	24398000	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3306000	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	315000	usd
CY2023Q3	us-gaap	Liabilities Liabilities	70038000	usd
CY2022Q3	us-gaap	Liabilities Liabilities	68968000	usd
CY2023Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	9000	usd
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	7000	usd
CY2023Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	432315000	usd
CY2022Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	402649000	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-438218000	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-404903000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-5894000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-2247000	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	64144000	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	66721000	usd
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	90415944	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	90415944	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	71181197	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	71181197	shares
CY2023Q1	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	26107000	usd
CY2022Q1	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	7269000	usd
CY2023Q1	us-gaap	Revenues Revenues	26107000	usd
CY2022Q1	us-gaap	Revenues Revenues	7269000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18869000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20381000	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4457000	usd
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5342000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	23326000	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	25723000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	2781000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-18454000	usd
CY2023Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	232000	usd
CY2022Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-20000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	232000	usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-20000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	3013000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	3013000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-18474000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-18474000	usd
CY2023Q1	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Diluted UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted	636000	usd
CY2023Q1	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic	636000	usd
CY2022Q1	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic	0	usd
CY2022Q1	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Diluted UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted	0	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	2377000	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-18474000	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.03
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.27
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.03
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.27
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	78640086	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	68138116	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	101189396	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	68138116	shares
CY2023Q2	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	7497000	usd
CY2022Q2	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	6216000	usd
CY2023Q2	us-gaap	Revenues Revenues	7497000	usd
CY2022Q2	us-gaap	Revenues Revenues	6216000	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17556000	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16630000	usd
CY2023Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4039000	usd
CY2022Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5339000	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	21595000	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	21969000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-14098000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-15753000	usd
CY2023Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	623000	usd
CY2022Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-6000	usd
CY2023Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	623000	usd
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-6000	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-13475000	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-15759000	usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	149000	usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-13624000	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13624000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-15759000	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-15759000	usd
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.15
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.15
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.23
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.23
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	90115859	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	90115859	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	69133700	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	69133700	shares
	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	33604000	usd
	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	13485000	usd
	us-gaap	Revenues Revenues	33604000	usd
	us-gaap	Revenues Revenues	13485000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	36425000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	37011000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	8496000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	10681000	usd
	us-gaap	Operating Expenses OperatingExpenses	44921000	usd
	us-gaap	Operating Expenses OperatingExpenses	47692000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-11317000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-34207000	usd
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	855000	usd
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-26000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	855000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-26000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-10462000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-34233000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	149000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Net Income Loss NetIncomeLoss	-10611000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-10611000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-34233000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-34233000	usd
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.50
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.50
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	84409667	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	84409667	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	68638651	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	68638651	shares
CY2023Q3	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	11250000	usd
CY2022Q3	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	40744000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1468000	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	usd
CY2023Q3	us-gaap	Revenues Revenues	12718000	usd
CY2022Q3	us-gaap	Revenues Revenues	40744000	usd
CY2023Q3	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	387000	usd
CY2022Q3	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	0	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17389000	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20283000	usd
CY2023Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4432000	usd
CY2022Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6270000	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	22208000	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	26553000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-9490000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	14191000	usd
CY2023Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	613000	usd
CY2022Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	55000	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	613000	usd
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	55000	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8877000	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	14246000	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	230000	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9107000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-9107000	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	14246000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	14246000	usd
CY2023Q3	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic	0	usd
CY2023Q3	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Diluted UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted	0	usd
CY2022Q3	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Diluted UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted	2931000	usd
CY2022Q3	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic	2931000	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9107000	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	11315000	usd
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.16
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.10
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.16
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	90287441	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	70217985	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	90287441	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	88592568	shares
	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	44854000	usd
	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	54229000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1468000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	usd
	us-gaap	Revenues Revenues	46322000	usd
	us-gaap	Revenues Revenues	54229000	usd
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	387000	usd
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	0	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	53814000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	57294000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	12928000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	16951000	usd
	us-gaap	Operating Expenses OperatingExpenses	67129000	usd
	us-gaap	Operating Expenses OperatingExpenses	74245000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-20807000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-20016000	usd
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	1468000	usd
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	29000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1468000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	29000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-19339000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-19987000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	379000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Net Income Loss NetIncomeLoss	-19718000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19718000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19987000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-19987000	usd
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.23
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.23
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.29
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.29
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	86390446	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	86390446	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	69170865	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	69170865	shares
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	3013000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-18474000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	640000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1338000	usd
CY2023Q1	cdtx	Operating Lease Right Of Use Amortization OperatingLeaseRightOfUseAmortization	262000	usd
CY2022Q1	cdtx	Operating Lease Right Of Use Amortization OperatingLeaseRightOfUseAmortization	234000	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	32000	usd
CY2022Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	39000	usd
CY2023Q1	us-gaap	Capitalized Contract Cost Amortization CapitalizedContractCostAmortization	475000	usd
CY2022Q1	us-gaap	Capitalized Contract Cost Amortization CapitalizedContractCostAmortization	0	usd
CY2023Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	0	usd
CY2022Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	1000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	20288000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3427000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-848000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1120000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	3192000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	657000	usd
CY2023Q1	cdtx	Accrued Indirect Tax Liabilities AccruedIndirectTaxLiabilities	261000	usd
CY2022Q1	cdtx	Accrued Indirect Tax Liabilities AccruedIndirectTaxLiabilities	353000	usd
CY2023Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	921000	usd
CY2022Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-1953000	usd
CY2023Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	36000	usd
CY2022Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-1004000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-290000	usd
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-252000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10898000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-23608000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	94000	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	84000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-94000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-84000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	17593000	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2023Q1	cdtx	Proceeds From Issuance Of Common Stock In Underwritten Public Offering ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering	8630000	usd
CY2022Q1	cdtx	Proceeds From Issuance Of Common Stock In Underwritten Public Offering ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering	500000	usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	14000	usd
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
CY2023Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	usd
CY2022Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1111000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	25976000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1722000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	26237000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-611000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	15245000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-24303000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	32731000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	62273000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	47976000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	37970000	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	25000	usd
CY2023Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	55000	usd
CY2022Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	16000	usd
CY2023Q1	cdtx	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction Net DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransactionNet	337000	usd
CY2022Q1	cdtx	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction Net DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransactionNet	720000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-10611000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-34233000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1435000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2016000	usd
	cdtx	Operating Lease Right Of Use Amortization OperatingLeaseRightOfUseAmortization	639000	usd
	cdtx	Operating Lease Right Of Use Amortization OperatingLeaseRightOfUseAmortization	476000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	57000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	77000	usd
	us-gaap	Capitalized Contract Cost Amortization CapitalizedContractCostAmortization	40000	usd
	us-gaap	Capitalized Contract Cost Amortization CapitalizedContractCostAmortization	0	usd
	us-gaap	Paid In Kind Interest PaidInKindInterest	0	usd
	us-gaap	Paid In Kind Interest PaidInKindInterest	1000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-350000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-524000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2388000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2120000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2567000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2870000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-483000	usd
	cdtx	Accrued Indirect Tax Liabilities AccruedIndirectTaxLiabilities	1897000	usd
	cdtx	Accrued Indirect Tax Liabilities AccruedIndirectTaxLiabilities	2993000	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-1277000	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-1324000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-2613000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-2412000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-595000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-512000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8076000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-35444000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	201000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	100000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-201000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-100000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	17256000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
	cdtx	Proceeds From Issuance Of Common Stock In Underwritten Public Offering ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering	8706000	usd
	cdtx	Proceeds From Issuance Of Common Stock In Underwritten Public Offering ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering	500000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	14000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	2222000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	17699000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-37266000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	32731000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	62273000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	50430000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	25007000	usd
	us-gaap	Interest Paid Net InterestPaidNet	0	usd
	us-gaap	Interest Paid Net InterestPaidNet	38000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	588000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3847000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	63000	usd
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	69000	usd
	cdtx	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction Net DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransactionNet	0	usd
	cdtx	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction Net DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransactionNet	720000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-19718000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-19987000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2231000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2859000	usd
	cdtx	Operating Lease Right Of Use Amortization OperatingLeaseRightOfUseAmortization	895000	usd
	cdtx	Operating Lease Right Of Use Amortization OperatingLeaseRightOfUseAmortization	724000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	79000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	114000	usd
	us-gaap	Capitalized Contract Cost Amortization CapitalizedContractCostAmortization	53000	usd
	us-gaap	Capitalized Contract Cost Amortization CapitalizedContractCostAmortization	1772000	usd
	us-gaap	Paid In Kind Interest PaidInKindInterest	0	usd
	us-gaap	Paid In Kind Interest PaidInKindInterest	1000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2655000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-314000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2901000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2776000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1662000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	6204000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1037000	usd
	cdtx	Accrued Indirect Tax Liabilities AccruedIndirectTaxLiabilities	3155000	usd
	cdtx	Accrued Indirect Tax Liabilities AccruedIndirectTaxLiabilities	3725000	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-402000	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-670000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-3956000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	7154000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-781000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-778000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9710000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7471000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	327000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	109000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-327000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-109000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	17256000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
	cdtx	Proceeds From Issuance Of Common Stock In Underwritten Public Offering ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering	8706000	usd
	cdtx	Proceeds From Issuance Of Common Stock In Underwritten Public Offering ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering	1698000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	14000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	720000	usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	2593000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	25976000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1615000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	15939000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-9195000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	32731000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	62273000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	48670000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	53078000	usd
	us-gaap	Interest Paid Net InterestPaidNet	0	usd
	us-gaap	Interest Paid Net InterestPaidNet	40000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	651000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	178000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3847000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	63000	usd
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	69000	usd
	cdtx	Proceeds From Public Offering Net Of Issuance Costs Prepaid Expenses Other Current Assets And Other Assets ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesOtherCurrentAssetsAndOtherAssets	0	usd
	cdtx	Proceeds From Public Offering Net Of Issuance Costs Prepaid Expenses Other Current Assets And Other Assets ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesOtherCurrentAssetsAndOtherAssets	10000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-14438000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	14000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	640000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	3013000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	15107000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	63000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	795000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-13624000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	2417000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	796000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-9107000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-5894000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	13104000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1165000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-18474000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-3705000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	69000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	852000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-15759000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-18543000	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	842000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	14246000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-2247000	usd
CY2023	dei	Auditor Firm AuditorFirmId	42

Files In Submission

Name	View Source	Status
0001610618-24-000041-index-headers.html	Edgar Link	pending
0001610618-24-000041-index.html	Edgar Link	pending
0001610618-24-000041.txt	Edgar Link	pending
0001610618-24-000041-xbrl.zip	Edgar Link	pending
cdtx-20231231.htm	Edgar Link	pending
cdtx-20231231.xsd	Edgar Link	pending
cdtx-20231231_g1.jpg	Edgar Link	pending
cdtx-20231231_g10.jpg	Edgar Link	pending
cdtx-20231231_g11.jpg	Edgar Link	pending
cdtx-20231231_g12.jpg	Edgar Link	pending
cdtx-20231231_g13.jpg	Edgar Link	pending
cdtx-20231231_g14.jpg	Edgar Link	pending
cdtx-20231231_g15.jpg	Edgar Link	pending
cdtx-20231231_g2.jpg	Edgar Link	pending
cdtx-20231231_g3.jpg	Edgar Link	pending
cdtx-20231231_g4.jpg	Edgar Link	pending
cdtx-20231231_g5.jpg	Edgar Link	pending
cdtx-20231231_g6.jpg	Edgar Link	pending
cdtx-20231231_g7.jpg	Edgar Link	pending
cdtx-20231231_def.xml	Edgar Link	unprocessable
cdtx-20231231_g8.jpg	Edgar Link	pending
cdtx-20231231_g9.jpg	Edgar Link	pending
exhibit1052023-12.htm	Edgar Link	pending
exhibit2312023-12.htm	Edgar Link	pending
exhibit3112023-12.htm	Edgar Link	pending
exhibit3122023-12.htm	Edgar Link	pending
exhibit3212023-12.htm	Edgar Link	pending
exhibit322023-12.htm	Edgar Link	pending
exhibit3222023-12.htm	Edgar Link	pending
exhibit9712023-12.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
cdtx-20231231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
cdtx-20231231_htm.xml	Edgar Link	completed
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
cdtx-20231231_cal.xml	Edgar Link	unprocessable
cdtx-20231231_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CDTX
Cidara Therapeutics, Inc. Stock $cdtx

2024 Q2 Form 10-K Financial Statement

#000161061824000041 Filed on April 22, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CDTX Cidara Therapeutics, Inc. Stock $cdtx

2024 Q2 Form 10-K Financial Statement

#000161061824000041 Filed on April 22, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CDTX
Cidara Therapeutics, Inc. Stock $cdtx